Tagrisso (osimertinib)

100 % legal and regulated
Secured logistics globally
24/7 track & trace delivery
Safe payment by bank transfer or credit card

We are registered as an independent intermediary for medicines with the Dutch Ministry of Health

Tagrisso (osimertinib)

How to buy Tagrisso: You can order Tagrisso (osimertinib) via TheSocialMedwork if the drug has not been approved and/or is not available in the patient's country. TheSocialMedwork - helping patients and doctors access the latest approved medicines and at the lowest price possible worldwide.

Manufacturer AstraZeneca
Disease Lung Cancer
Indication Advanced or metastatic NSCLC with T790M mutation
Mode of Action Kinase inhibitor (targeted therapy)
Approval Status EMA approved (EU); FDA approved (USA); TGA approved (AUS)
CAS Number 1421373-65-0
HS Code 30049000
Strength 40 mg, 80 mg

Who is osimertinib for?

Tagrisso (osimertinib) is indicated for the treatment of advanced or metastatic NSCLC in patients with epidermal growth factor receptor (EGFR) T790M mutation [1][2][3].

Recommended dose

Complete information about Tagrisso (osimertinib) dosage and administration can be found here [1][2][3].
The standard dosage is:
  • 80 mg orally once daily
Consult your treating doctor for personalised dosing.

What is osimertinib and how does it work?

Tagrisso (osimertinib) is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC) [1][2][3].
It blocks the activity of EGFR, which normally controls growth and division of cells. In lung cancer cells, EGFR is often overactive, causing uncontrolled division of cancer cells. By blocking EGFR, osimertinib helps to reduce the growth and spread of the cancer. Unlike most other tyrosine kinase inhibitors, Tagrisso (osimertinib) is active against cancer cells with the T790M mutation in the EGFR gene [4].

What is osimertinib's approval status?

Tagrisso (osimertinib) was approved by:
  • FDA (USA) on November 13, 2015 [5] with accelerated approval and on March 30, 2017 [6] with regular approval
  • EMA (EU) on February 2, 2016 [4]
  • TGA (AUS) on August 3, 2016 [3]
for the treatment of metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC).
The approvals of osimertinib for T790M mutation positive NSCLC were based on two single-arm, open-label clinical studies, AURAex (Phase II Extension cohort, (n=201)) and AURA2 (n=210) involving patients who had progressed on one or more prior systemic therapies [1][2][3].
In the 411 pre-treated EGFR T790M mutation-positive patients, the total overall response rate (ORR) was 66 % [95 % CI: 61, 71] — 62 % [95 % CI: 55, 68] in AURAex and 70 % [95 % CI: 63, 77] in AURA2. In patients with a confirmed response the median duration of response (DoR) was 12.5 months [95 % CI: 11.1, non estimable]. The medianprogression free survival (PFS) was 11.0 months [95 % CI (9.6, 12.4] [3].
A third study (AURA3) involved 419 patients and compared the efficacy of Tagrisso (osimertinib) in preventing the cancer from worsening, comparing it with a platinum-based chemotherapy (the standard treatment for NSCLC). In patients taking Tagrisso, the PFS was 10.1 months compared with 4.4 months in patients on chemotherapy. There were no significant differences in overall survival. The objective response rate was 71 % [95 % CI: 65, 76] in patients taking osimertinib and 31 % [95 % CI: 24, 40] in patients on standard chemotherapy. The duration of response was 9.7 months [95 % CI: 8.3, 11.6] on osimertinib vs 4.1 months [95 % CI: 3.0, 5.6] [3].
The most common side effects are diarrhoea, rash, dry skin, paronychia (nail infection), itching, stomatitis (inflammation of the lining of the mouth) and a decrease in the levels of white blood cells and platelets [4].
[1] Summary of Product Characteristics [FDA]: Tagrisso (osimertinib), AstraZeneca, Mar. 2017.
[2] Summary of Product Characteristics [EMA]: Tagrisso (osimertinib), AstraZeneca, May 2017.
[3] Summary of Product Characteristics [TGA]: Tagrisso (osimertinib), AstraZeneca, Dec. 2016.
[4] EMA. Human Medicines: Tagrisso (osimertinib), 17/02/2016 (last update: 02/03/2016), cited on 20/06/2017.
[5] FDA News Release: FDA approves new pill to treat certain patients with non-small cell lung cancer, 13/11/2015.
[6] FDA. Approved Drugs: Tagrisso (osimertinib), 30/03/2017, cited on 20/06/2017.

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.

How can we help?

★ ★ ★ ★ ★

We've received requests for support from patients and doctors in over 120 countries, and delivered medicines to 6 continents. They've given us a 5 star rating for our service. Read what our friends from around the world are saying...

"My experience has been excellent. TheSocialMedwork were totally knowledgeable about the medicine I was looking for, and how to get it delivered to me quickly and easily. I UNCONDITIONALLY recommend TSM to anyone, it is truly a world-class organisation."

— Charles, USA

"During the transaction process I was very well informed by TheSocialMedwork team. They have put so much effort to ensure the best service was offered to me. Moreover the medicine I ordered was imported two weeks earlier. I highly recommend TheSocialMedwork."

— Tomasz, Poland

"I hope you know how needed you are and what it means to get a prompt, succinct and helpful reply. You are our hero. You have given us realistic hope in obtaining needed drugs in a timely way."

— Regina, US

"TheSocialMedwork were so helpful in getting the right medication to me, expediting its delivery, and keeping in touch. They simply can't do enough to help you. I would not hesitate to recommend TheSocialMedwork to anybody. Lovely people."

— Stephen, UK

"Totally awesome! Keep up the great work you're doing!"

— Dee, Australia

"When the doctor tells you that there are no treatments left to try, search further - there may be new treatments in other countries."

— Charlotte, The Netherlands

"TheSocialMedwork's professional capabilities, kindness and patience deserve our gratitude and respect."

— Haoyu, China

"My daughter died at the age of 21 because she couldn't get the treatment that might have saved her life. Now TheSocialMedwork might be able to help people like Abigail to get the best treatment."

— Frank, Virginia, USA

"The team is highly professional, friendly and will take care of everything. More options for doctor and patients. This service is transparent, unique and necessary. Keep it up!"

— Pa Tric, Germany

"Excellent communication and clarifications given every time when requested. They also provide fantastic support and updates from the start till the end of the process of the medicine provisioning."

— Milos, Serbia & Montenegro

Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM
Registered as a USA Delaware LLC.

Our service uses cookies.